| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11025711 | Journal of Ethnopharmacology | 2019 | 32 Pages |
Abstract
Main findings: Aidi injection plus paclitaxel-based chemotherapy, especially TP can significantly improve the clinical efficacy and QOL in patients with advanced NSCLC. Aidi injection can relieve the risk of hematotoxicity, gastrointestinal toxicity and liver injury in patient with NSCLC receiving paclitaxel-based chemotherapy. Based on the optimization of efficacy and safety, the optimal usage may be 50â¯ml/time and 14 days/2 cycles. Aidi injection may have attenuation and synergistic efficacy to paclitaxel-based chemotherapy.285
Keywords
DCRAidi injectionGinsenoside Rg1 (PubChem CID: 441923)gemcitabine and cisplatinCBMORRRCTCNKIKPSADRsREMVIPQOLGinsenoside Rh2 (PubChem CID: 119307)Quality of lifeAmIPFsRandomized controlled trial (RCT)Randomized controlled trialISIGrading of Recommendations Assessment, Development and EvaluationNo changeProgression free survivaloverall survivalprogressive diseaseTaxolPublication biasRECISTStatistical methodWorld Health OrganizationNon-small cell lung cancer (NSCLC)NSCLCNon-small cell lung cancerconfidence intervalMeta-analysisRandom-effects modelFixed-effects modelSystematic reviewResponse Evaluation Criteria in Solid TumorsGradeKarnofsky performance scaleobjective response rateDisease control rateRisk ratiosAdverse drug reactionsWeb of SciencePartial responsecomplete responsePaclitaxelFEMWHO
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Zheng Xiao, Chengqiong Wang, Minghua Zhou, Shanshan Hu, Yuan Jiang, Xiaorong Huang, Nana Li, Jihong Feng, Fushan Tang, Xiaofan Chen, Jie Ding, Ling Chen, Yuhe Wang, Xiaofei Li,